Pancreatic Cancer

Mary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.

Mary B. Beasley, MD, discusses the prevalence of NRG1 fusions in non–small cell lung cancer and pancreatic cancer.

Shubham Pant, MD, MBBS, discusses next-generation sequencing in pancreatic cancer, highlighting the importance of targeting RAS mutations when applicable.

Tanios S. Bekaii-Saab, MD, discusses the evolution of frontline treatment in advanced pancreatic cancer.

Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.

RMC-9805 was proven safe and active in patients with previously treated, KRAS G12D–mutant pancreatic ductal adenocarcinoma.

The FDA has granted orphan drug designation to IMM-1-104 for pancreatic cancer.

MesoPher cell therapy led to a 2-year recurrence-free survival rate of 64% and low-grade AEs in resected pancreatic cancer following chemotherapy.

LODER plus chemotherapy led to responses and improved overall survival in unresectable, locally advanced pancreatic cancer.

The FDA has granted fast track designation to narmafotinib for the treatment of advanced pancreatic cancer.

First-line IMM-1-104 combined with modified gemcitabine/nab-paclitaxel elicited both partial and complete responses in patients with pancreatic cancer.

Males harboring BRCA1/2 pathologic variants have a higher risk of developing select cancers but are less likely to undergo genetic testing.

The FDA granted fast track designation to IMM-1-104 for first-line pancreatic ductal adenocarcinoma.

Two late-stage trials investigating the efficacy and safety of pamrevlumab in pancreatic cancer failed to meet their primary end points of OS.

Eileen M. O'Reilly, MD, details how RAS-directed therapy could potentially change the pancreatic cancer landscape and highlights updated data in the space.

S. Lindsey Davis, MD, highlights data with the mTOR inhibitor sapanisertib and Aurora A kinase inhibitor alisertib in patients with solid tumors.

Mitazalimab plus mFOLFIRINOX yielded early efficacy signals and a manageable safety profile for the frontline treatment of patients with mPDAC.

MPO may be a predictive biomarker for survival for treatment with CM24, nivolumab, and chemotherapy in second-line pancreatic ductal adenocarcinoma.

Frontline mitazalimab plus mFOLFIRINOX generated an OS benefit and prolonged DOR in patients with metastatic pancreatic ductal adenocarcinoma.

Rocio Garcia-Carbonero, MD, discusses the rationale for the phase 2b VIRAGE trial in patients with metastatic pancreatic cancer.

XB2001 plus chemotherapy improved safety and was tied to a trend toward improved overall survival in pretreated advanced pancreatic cancer.

E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses the recent clinical data with zenocutuzumab in patients with NRG1 fusion–positive pancreatic cancer and the impact the approval of this agent could have on the landscape.

E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses current standard therapeutics for patients with NRG1 fusion–positive pancreatic cancer.

E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses the benefits and challenges of DNA and RNA testing for NRG1 fusions in patients with pancreatic cancer.